Volume 25, Number 10—October 2019
Research
Sporotrichosis in the Highlands of Madagascar, 2013–20171
Table 1
Criteria used to classify cases of sporotrichosis in the Highlands of Madagascar, 2013–2017*
Criteria | Description |
---|---|
Clinical | |
Major | Cutaneous: lymphocutaneous form defined as a papule or pustule or a subcutaneous nodule at the inoculation site, then ulceration with erythematous edges and purulent secretion. Secondary lesions arise along the path of regional lymphatic vessels. Fixed or cutaneously disseminated. |
Extracutaneous: disseminated, osteoarticular, ocular. | |
Minor | Mucosal: nasal septum, with bloody secretions and detachment of crusts. Conjunctivitis, with granulomatous lesions accompanied by a serous-purulent discharge, redness, lid edema, and preauricular and submandibular lymph node enlargement. |
Primary pulmonary sporotrichosis: similar to that of tuberculosis. Radiologic patterns include cavitary disease, tracheobronchial lymph node enlargement, and nodular lesions. Vegetative, verrucous, infiltrated plaque, or tuberous lesion. |
|
Mycologic and histologic | |
Major | Molecular evidence of Sporothrix schenckii on PCR with specific primers (targeting topoisomerase II) or ITS sequencing, directly from clinical samples or from a positive culture of a fungus morphologically suggestive of Sporothrix spp. |
MALDI-TOF mass spectrometry identification of S. schenckii from a positive culture of a fungus morphologically suggestive of Sporothrix spp. | |
Minor | Budding yeast cells with the characteristic cigar-shaped buds observed on direct microscopic examination or histologic analysis. |
Direct examination of pus and/or histologic analysis showing asteroid bodies (Splendore-Hoeppli reaction). | |
Positive culture of a fungus morphologically suggestive of Sporothrix spp. from a clinical sample without molecular or MALDI-TOF mass spectrometry confirmation. |
|
Classification | |
Confirmed | >1 of the major clinical criteria and >1 of the major mycologic criteria or 1 minor clinical criterion and >1 of the major mycologic criteria. |
Probable | >1 of the major clinical criteria and 1 minor mycologic or histologic criterion and a complete or partial response to antifungal therapy. |
Possible | >1 of the major clinical criteria without any (major or minor) mycologic or histologic criteria or >1 of the minor clinical criteria without any (major or minor) mycologic or histologic criteria and a complete or partial response to antifungal therapy. |
Clinical response to antifungal therapy | |
Cure | Complete resolution of all lesions. |
Major response | Substantial improvement of most lesions with a substantial decrease in subcutaneous nodules. |
Minor response | Mild improvement of most lesions with a smaller decrease in subcutaneous nodules than for a major response. |
Failure | Stabilization of the lesions after >3 months of antifungal therapy or worsening of the lesions after >3 months of antifungal therapy. |
*ITS, internal transcribed spacer; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight.
1Preliminary results from this study were presented at the 20th ISHAM Conference; June 29–July 5, 2018; Amsterdam, the Netherlands (abstract no. S1.4d).